VYNE - VYNE Therapeutics selects lead candidate for immuno-inflammatory treatment program

2023-05-01 11:40:49 ET

• • VYNE Therapeutics ( NASDAQ: VYNE ) has selected a lead candidate for its oral BD2-selective bromodomain and extra-terminal inhibitor program, VYN202, used to treat immuno-inflammatory conditions. VYNE exclusively licensed the BD2-selective BET inhibitors from Tay Therapeutics, following positive preclinical data, including results from animal models in various autoimmune disorders.
• • • ( VYNE ) is trading 5.3% higher .
    In addition, VYNE has acquired the rights to several other BD2-selective BET inhibitor compounds that have promising molecular profiles. The company may choose to develop these compounds in the future at its discretion.
• • VYN202 is an oral drug that targets BET proteins involved in overproduction of pro-inflammatory proteins linked to autoimmune and autoinflammatory diseases. It selectively inhibits BD2 over BD1 to avoid gastrointestinal and hematological toxicities associated with previous systemic BET inhibitors. BET inhibitors have potential to treat immuno-inflammatory and fibrotic diseases according to preclinical models.
• • VYNE has started IND-enabling studies for VYN202 and aims to submit an IND by year-end. The license agreement with Tay grants VYNE exclusive worldwide rights to the compounds in its InhiBET platform, including VYN202, for all human disease applications.
• • Press Release

For further details see: